Luma Therapeutics Announces Positive Clinical Data for the Illuvinate System, a New In-Home Treatment for Psoriasis

Results Demonstrate Significant Healing That Is Maintained Even Following Treatment

MILLBRAE, Calif. & WASHINGTON–(BUSINESS WIRE)–Luma Therapeutics, a company dedicated to eradicating suffering from inflammatory skin disease, today announced positive results from three clinical studies evaluating in-home treatment of patients with plaque psoriasis. Findings from the studies, which assessed the company’s FDA-cleared illuvinate™ System, were presented during the annual meeting of the American Academy of Dermatology Annual meeting in Washington, D.C.

The results of the third study, presented by Tina Bhutani, M.D., of the UCSF Medical Center in San Francisco, Calif., demonstrated significant improvement in symptoms and appearance for plaques treated with illuvinate, with healing that was maintained eight weeks following treatment.

The multi-site study measured clinical outcomes from 52 target psoriasis plaques in 26 patients, with an untreated plaque on each patient serving as the control. In the study, Target Plaque Assessment (TPA) score was assessed at the beginning of the study and over a period of six weeks while using illuvinate. This score included assessments of scale, redness and thickness of plaques. Findings showed a 66% reduction in TPA score at six weeks for plaques treated with illuvinate compared with a 15% reduction for untreated plaques. At 14 weeks (eight weeks following treatment), results showed a 70% reduction in TPA score, suggesting a therapeutic effect sustained beyond the treatment period. Nearly one-third of patients had complete clearance of plaque at 14 weeks.

“These data suggest that illuvinate provides Goeckerman-like healing for patients with plaque psoriasis, which continues even beyond the treatment period,” said Dr. Bhutani. “I believe illuvinate offers an exciting new prospect for many patients looking for an alternative to biologics and creams.”

“Psoriasis is a challenging condition to manage, and many patients feel disheartened by the inability to find a treatment option that works and provides lasting long relief,” said Dr. Jeffrey Sugarman, M.D., Ph.D., of Redwood Family Dermatology who served as the principal investigator of the study. “I have been impressed by the results, and particularly the durability of results, that I have seen in patients who have used the system.”

“As a psoriasis sufferer myself, I know the frustration these patients feel with the treatment options currently available to them,” said founder and CEO Evan Anderson. “We are pleased that the positive results of these studies show illuvinate’s innovative light therapy system delivers significant benefit including sustained, durable healing, suggesting that illuvinate has the potential to improve quality of life for these patients.”

About illuvinate™

The FDA-cleared illuvinate System is an innovative treatment designed to provide lasting relief from psoriasis symptoms. Inspired by the Goeckerman Regimen, a 100-year-old proven therapy that results in long periods of remission lasting over a year.1 However this treatment is only available at a handful of specialized centers and often requires multiple day-long clinic visits over a period of weeks, creating barriers to widespread adoption. Luma Therapeutics has redesigned the key elements of the Goeckerman Regimen to make it available to patients in their own home.

Illuvinate has been demonstrated to reduce local inflammation, rehydrate the skin and restore normal skin cells. The system includes patented hydrating technology, a narrowband UV LED light system, and a proprietary app-based dosing algorithm. The therapy is applied for just minutes each day over a six-week period from the comfort and convenience of home. The system can now be prescribed either by a dermatologist or via Luma’s telehealth provider, HealthLens.

About Luma Therapeutics

Based in Silicon Valley, Luma Therapeutics is a privately held medical technology company committed to developing innovative and convenient therapies for the millions of people around the world suffering from inflammatory skin disease. In collaboration with Mayo Clinic, Luma Therapeutics developed the FDA-cleared illuvinate™ System to offer patients with psoriasis an effective treatment option that can be used at home. The company has also been supported by StartX accelerator and the Rosenman Institute at QB3. For more information visit www.lumatherapeutics.com.

1 Gupta, Rishu, et al. “The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis.” Journal of Visualized Experiments, no. 77, 2013, doi:10.3791/50509.

Contacts

Durae Hardy
durae@healthandcommerce.com
707.337.1903


Luma begins launch of ultraviolet light-based plaque psoriasis treatment

Luma Therapeutics and the illuvinate™ system were featured on FierceBiotech after the Dec. 5, 2018 launch of the innovative light-based therapy for the treatment of plaque psoriasis.

“The smartphone-controlled device combines narrowband ultraviolet light with a hydrogel that helps keep moisture in the skin during use. The UVB light reduces psoriasis symptoms by preventing overactive immune cells from releasing growth factors into the skin.”

Visit their website to view the full article.

About FierceBiotech

FierceBiotech provides end-to-end coverage of biotech and medtech from pre-clinical science through clinical testing and regulatory approval.


Luma Therapeutics Announces Launch of the illuvinate System, a New In-Home Treatment for Plaque Psoriasis

FDA-Cleared Treatment is Based on Proven Techniques and Designed for Lasting Remission

MILLBRAE, Calif. – December 5, 2018 – Luma Therapeutics, a company dedicated to eradicating suffering from inflammatory skin disease, today announced the launch of an innovative light-based therapy for the treatment of plaque psoriasis. The company’s FDA-cleared breakthrough technology, the illuvinate™ System, is an in-home treatment designed to provide lasting relief from psoriasis symptoms.  Illuvinate can now be prescribed either by a dermatologist or via Luma’s telehealth provider, HealthLens.

Psoriasis – an inflammatory condition resulting in painful, raised patches of skin often found on the scalp, knees, elbows, and lower back – affects two to three percent of the world’s population and 7.5 million people in the U.S. alone. In addition to the discomfort and embarrassment endured by psoriasis sufferers, the condition is associated with depression, cardiovascular disease and Type II diabetes.[i]

Luma Therapeutics was founded with a vision to end the suffering of patients with inflammatory skin conditions, starting with psoriasis.

“As a psoriasis sufferer, I knew how important it was to find a better solution than what was currently available,” said founder and CEO Evan Anderson. “We are pleased that the illuvinate System is now available to help people in California with psoriasis, a condition that often has a serious impact on quality of life. We look forward to launching nationally next year.”

Current common treatments for psoriasis fall short: topical steroid treatments can be messy and ineffective, and many patients are reluctant to take medications that may have long-term side effects. Other treatments are only available in a clinical setting, presenting an obstacle to consistent adherence.

The most effective treatment for psoriasis is the Goeckerman Regimen, a 100-year-old proven therapy that results in long periods of remission lasting between eight months to over a year.[ii] However this treatment is only available at a handful of specialized academic centers and often requires multiple day-long clinic visits over a period of weeks, creating barriers to widespread adoption. Luma Therapeutics has redesigned the key elements of the Goeckerman Regimen to make it available to patients in their own home.

Jeffrey Sugarman, M.D., Ph.D., of Redwood Family Dermatology in Santa Rosa, Calif., and UCSF Health in San Francisco, serves as Luma Therapeutic’s Chief Medical Officer and principal investigator of studies of the illuvinate System.

“Psoriasis is a chronic condition for which there is no cure, and there is a need for better treatment options. Most available treatments require ongoing compliance in order to achieve optimal results, and many patients are hesitant to consistently use medications, which may have long-term side effects, ” said Dr. Sugarman. “As a result, patients become discouraged and stop seeking treatment from a dermatologist. I believe that the illuvinate System will be a great option for many patients.”

Dr. Sugarman’s patient Georgios Kladis participated in the clinical trials of the system.

“I have had psoriasis for many years and have tried all kinds of psoriasis treatments, and none of them worked. The illuvinate System cleared my skin quickly,” said Georgios. “Even more exciting was how long my skin stayed clear after the treatment. I like that it does not involve the side effects of a drug and takes just minutes a day in my home. I would recommend it to other people dealing with psoriasis.”

Illuvinate has been demonstrated to reduce local inflammation, rehydrate the skin and restore normal skin cells. The system includes patented hydrating technology, a narrowband UV LED light system, and a proprietary app-based dosing algorithm. The therapy is applied for just minutes each day over a six-week period from the comfort and convenience of home.

“We are excited to partner with Luma Therapeutics to offer the illuvinate System to psoriasis patients,” said Christopher Schmidt, M.D., board-certified dermatologist and founder of HealthLens, a multi-specialty telemedicine platform, as well as a clinical faculty member of Stanford University.  “Telehealth is the next frontier in medicine, enabling patients easy access to treatments that can dramatically improve their condition and quality of life. Dermatology is uniquely suited to telehealth. In fact, recent research concluded that an online, collaborative health model was as effective as in-person management in improving clinical outcomes among patients with psoriasis.”[iii]

About Luma Therapeutics

Based in Silicon Valley, Luma Therapeutics is a privately held medical technology company committed to developing innovative and convenient therapies for the millions of people around the world suffering from inflammatory skin disease. In collaboration with Mayo Clinic, Luma Therapeutics developed the FDA-cleared illuvinate™ System to offer patients with psoriasis an effective treatment option that can be used at home. The company has also been supported by StartX accelerator and the Rosenman Institute at QB3.  For more information visit https://illuvinate.com/.

About HealthLens

HealthLens provides medical device companies with custom telemedicine solutions to access large numbers of patients and providers without the need for a traditional sales force. For more information visit www.HealthLens.com.

# # #

Media Contact:
Sierra Smith
Health+Commerce
408.540.4296
sierra@healthandcommerce.com

 

Sources:
[i] “Comorbidities Associated with Psoriatic Disease.” National Psoriasis Foundation, www.psoriasis.org/about-psoriasis/related-conditions.
[ii] Gupta, Rishu, et al. “The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis.” Journal of Visualized Experiments, no. 77, 2013, doi:10.3791/50509.
[iii] Armstrong, W. “Online vs In-Person Care for Adults With Psoriasis.” JAMA, American Medical Association, 5 Oct. 2018, jamanetwork.com/journals/jamanetworkopen/fullarticle/2705854.


Luma’s illuvinate Now Available for Drug-Free Plaque Psoriasis Treatment at Home

Luma Therapeutics and the illuvinate™ system were featured on Medgadget after the Dec. 5, 2018 launch of the innovative light-based therapy for the treatment of plaque psoriasis.

“Patients who are prescribed the system, either by their dermatologist or through Luma’s telemedicine partner [HealthLens], are expected to use the device once a day on their inflamed problem spots. The system works to limit inflammation, rebuild healthy cellular structure, and hydrate the skin so it’s nice and healthy.”

Visit their website to view the full article.

About Medgadget

Since 2004, Medgadget has been reporting on medical technology from around the world. It covers the latest medical devices and approvals, technology breakthroughs and discoveries, conducts exclusive interviews with med tech leaders, and files reports from healthcare conferences.


Innovation is more than skin deep for this medical device startup

Luma Therapeutics and the illuvinate™ system were featured in the San Francisco Business Times after the Dec. 5, 2018 launch of the innovative light-based therapy for the treatment of plaque psoriasis.

“Luma’s ‘Illuvinate’ system is an early player in the use of smartphones to deliver not only new ways to diagnose diseases but to actually treat certain conditions.”

Visit their website to view the full article.

About San Francisco Business Times

The San Francisco Business Times website provides local breaking business news, this week's stories from San Francisco Business Times and other popular features from the weekly edition.


Podcast: Launching Luma Therapeutics & its Psoriasis Patch

Evan Anderson, CEO and Board Member of Luma Therapeutics, was featured in episode 5 of The Health Technology Podcast from the Rosenman Institute. In the interview, Evan discusses why he founded Luma Therapeutics and the illuvinate System, a revolutionary light therapy for those suffering from psoriasis.

Visit their website to listen to the full podcast.

About The Rosenman Institute

A nonprofit initiative at UC San Francisco. Our mission is to drive innovation and improve patient care by helping health technology entrepreneurs develop technologies from concept to commercialization.


FDA Clears First System to Combine Smartphone Controlled UVB Light with Occlusive Hydrating Gels to Treat Inflammatory Skin Disease

FOR IMMEDIATE RELEASE: June 6, 2018

New Phototherapy System Combines Proprietary Hydrogel with Narrowband UVB LED Light for Safe, Effective at-Home Skin Treatment

Millbrae, CA – June 6, 2018 Luma Therapeutics, a company dedicated to eradicating suffering from inflammatory skin disease, announces the immediate launch of illuvinateTM, an innovative and modern twist on a safe and effective treatment called the Goeckerman regimen, invented over 100 years ago by a dermatologist at the Mayo Clinic.

Backed by strong clinical trial data, this system enables those suffering from chronic skin conditions such as psoriasis, eczema or vitiligo to experience clear skin after performing therapy in the comfort of their own homes in just minutes a day. By combining a narrowband UVB LED light with patented hydrogels containing coal tar micro-globules, illuvinate increases the skin’s hydration, decreases inflammation, and suppresses overactive immune cells.

As a digital therapeutic, the system is controlled by a smartphone app with a doctor’s prescription and Luma’s patented algorithm to modify the dose based on patient feedback.  The illuvinate light module attaches magnetically to multi-day wear illuvinate hydrogels, freeing the user to relax during treatment sessions. In addition, users’ have the ability to share their progress with photographs taken on the app.

Backed by over $6 million in investments from groups such as the Mayo Clinic and Stanford-StartX, illuvinate offers a unique solution for those that don’t want to use messy topicals or pharmaceuticals with potentially harmful side effects. Dr. Jeffrey Sugarman, MD, PhD of Redwood Family Dermatology and UCSF Health expressed his enthusiasm for offering this new technology to his patients. “The illuvinate system was inspired by the Goeckerman regimen and I’ve been encouraged by the strong clinical data supporting its use in the home for plaque psoriasis. It is easy and convenient to use. It has the potential to help millions of people suffering from psoriasis.”

The illuvinate system was created after Evan Anderson, founder and CEO of Luma Therapeutics, tried multiple options for treating his psoriasis. Evan Anderson stated “I started Luma because I wasn’t happy with available treatments. Clinical trial patients have provided encouraging feedback and we’ve been granted multiple patents for our technology. Now I believe illuvinate is poised to make a meaningful impact on people suffering from inflammatory skin disease.” Currently available for purchase in California, a nationwide launch is planned for early 2019.

Luma Therapeutics is a privately held medical device company committed to developing innovative and convenient light therapies for the millions of people around the world suffering from inflammatory skin disease.  Learn more atwww.lumatherapeutics.com and www.illuvinate.com.

MEDIA CONTACT

Anita Greggs Perez
Luma Therapeutics
480-225-6610 – agreggs@lumatherapeutics.com


Luma Therapeutics Initiates Clinical Trial for People with Mild-to-Severe Psoriasis

FOR IMMEDIATE RELEASE

Luma Therapeutics Initiates Clinical Trial for People with Mild-to-Severe Psoriasis

MILLBRAE, CA – June 14, 2017 – Luma Therapeutics, Inc., a medical device company developing innovative technologies for inflammatory skin disease, announced today the initiation of a multi-center randomized study to demonstrate the safety and efficacy of the Luma Light System in treating psoriasis. This trial will build upon positive results from two previous feasibility studies using earlier versions of the Luma Light System.

Patients enrolled in the trial will treat their psoriasis at home with the Luma Therapeutics System of occlusive hydrogel patches, a light, and an app that controls the light. Narrowband UV-B light has been shown to decrease the immune response, and the occlusive hydrogel patches can reduce inflammation and decrease cell growth. The combination of these treatments may result in remission of psoriasis.

“We started Luma Therapeutics to empower people suffering from inflammatory skin disease,” said Evan Anderson, Founder and CEO of Luma Therapeutics, “and this trial is an important milestone as we plan to move forward to submit the Luma System to the US Federal Drug Administration for regulatory clearance this year.”

More information about the Luma Therapeutics System and the clinical trial can be found at http://lumaclinicaltrial.com.

About Luma Therapeutics: Luma Therapeutics, Inc. is a medical device company based in Millbrae, CA. Founded in 2013, Luma Therapeutics is developing light therapy systems to improve inflammatory skin disease, starting with psoriasis.

Luma Therapeutics (www.lumatherapeutics.com)
10 Rollins Rd, Suite 120, Millbrae, CA 94030
650-260-8245 – customercare@lumatherapeutics.com


Luma Therapeutics Raises $2M Round A and Announces Addition of Matthew E. Likens, Former CEO of Ulthera to Board

FOR IMMEDIATE RELEASE

Luma Therapeutics Raises $2M Round A and Announces Addition of Matthew E. Likens, Former CEO of Ulthera to Board

MILLBRAE, CA – February 21, 2017 – Luma Therapeutics, Inc., a medical device company developing innovative technologies for inflammatory skin disease, announced today that it has raised $2 million in private financing with new and existing investors. The company will use the proceeds to continue collecting clinical evidence supporting its flagship product, the Luma Light System™, and preparing the system for commercial release.

In other news, Luma announced that Matt Likens, has joined its Board of Directors. Mr. Likens is a principal at Likens Healthcare and Management Consulting, LLC. He was the President and CEO of Ulthera, Inc. from 2006 to 2016. Prior to Ulthera, Mr. Likens was employed at GMP Companies, Inc. as President of GMP Wireless Medicine from 2001 to 2006 and Executive Vice President, Operations from 2001 to 2004. Mr. Likens previously served in various capacities at Baxter Healthcare Corporation from 1978 to 2001, and was President of Baxter’s Renal U.S. business upon his departure in January, 2001.

The Luma Light System consists of the Luma Light and Luma Patch. The Luma Light is an array of ultraviolet-B light-emitting diodes (LEDs) that connect to an app on a patient’s phone to control and monitor the applied dose, based on a doctor’s prescription. The Luma Patch is a patented occlusive hydrogel dressing designed to increase skin hydration and reduce inflammation.

Luma Therapeutics has conducted two small pilot studies and recently started a multi-center randomized study to demonstrate the safety and efficacy of the Luma Light System in treating psoriasis, one of the most prevalent inflammatory skin diseases, in patients’ homes. The company plans to submit the system to the U.S. Food and Drug Administration for regulatory clearance this year.

Matt Likens stated, “I was impressed by the early clinical data and by the team’s commitment to helping people with inflammatory skin disease. I am thrilled to join the board and provide guidance as the company moves towards commercialization.”

“We started Luma Therapeutics to empower people suffering from inflammatory skin disease by putting light-based therapy in their hands,” said Evan Anderson, Founder and CEO of Luma Therapeutics. “The addition of Matt to our board and raising our Series A financing validates our vision and takes us another step towards helping people with the Luma Light System™.”

About Luma Therapeutics: Luma Therapeutics, Inc. is a medical device company based in Millbrae, CA. Founded in 2013, Luma Therapeutics is developing light therapy systems to improve inflammatory skin disease, starting with psoriasis.

Luma Therapeutics (www.lumatherapeutics.com)
10 Rollins Rd, Suite 120, Millbrae, CA 94030
650-260-8245 – customercare@lumatherapeutics.com


Luma Therapeutics wins “Shark Tank” Business Competition at Dermatology Entrepreneurship Conference

MILLBRAE, CA. – March 15, 2016 – Luma Therapeutics, Inc., a digital health company focused on the development of light therapy technologies for the treatment of inflammatory skin disorders, announced the winning of a business plan competition among top innovators at the 2nd Annual Dermatology Entrepreneurship Conference on March 3rd, 2016. The competition received over 30 applications and the veteran panel of judges chose 4 finalists who presented in a “shark tank” format.

Luma Therapeutics CEO Evan Anderson, a psoriasis patient and a medical device developer, started the company with the goal of bringing more effective therapies to the 40 million people in the US with inflammatory skin disorders. Luma’s first product is a patent-protected system that combines ultraviolet light therapy controlled by a smart phone app and occlusive coal tar patches to treat psoriasis quickly and provide extended plaque remission.

With traditional methods, treating psoriasis through multiple modalities is usually effective but also time-consuming, cumbersome and expensive. The Luma Therapeutics System is designed to make this type of treatment easy, fast and administered in the comfort of a patient’s home.

Jeffrey Sugarman MD, PhD, a dermatologist in Santa Rosa, CA and Luma’s Chief Medical Officer said, “I have many patients who have tried different topical psoriasis therapies with disappointing results.  Luma receiving the top prize at the Dermatology Entrepreneurship Conference is an important step towards commercialization and ultimately providing psoriasis sufferers with much needed effective, affordable and convenient therapy.”

“Winning the Dermatology Shark Tank against such strong competition and with experienced judges validates the promising therapy that Luma is bringing to millions of skin disease sufferers,” Mr. Anderson said.

Development of the Luma Therapeutics first commercial product is in progress and enrollment in the next clinical trial is expected to begin over the next few months.

About Luma Therapeutics
Luma Therapeutics, Inc. is a digital health medical device company based in Millbrae, CA. Founded in 2013, Luma Therapeutics is developing light therapy systems to improve inflammatory skin disease.

Luma Therapeutics, Inc. (www.lumatherapeutics.com)
10 Rollins Rd, Suite 120, Millbrae, CA 94030
650-260-8245 – customercare@lumatherapeutics.com

For more information about the Dermatology Entrepreneurship Conference, visit www.dermsummit.com/2016/dec/